MAPT and Alzheimer disease: While these studies suggest a potential role for targeting tau with antibodies in AD and other tauopathies, it remains unclear if the age-dependent development of pathology in the employed transgenic models is due a transmissible spread of pathologic tau and/or to different rates of cell autonomous development of pathology.